The clinical trial to examine the densities of AMPA receptors in epilepsy patients with [11C]K-2

Not Applicable

Recruiting

• Conditions: epilepsy

• Registration Number: JPRN-UMIN000031624
• Lead Sponsor: Yokohama City University hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-04-01
• Study Completion: 2020-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who have experienced the electric stimulation therapy 2. Patients who have severe renal dysfunction (Serum Cre>1.5) 3. Patients who have severe liver dysfunction (AST and ALT>150) 4. Patients who have severe cardiovascular disorder 5. Patients who have tatoo 6. Claustrophobic patients 7. Patients who can not agree with contraception during 7days after [11C]K-2 PET 8. Patients who take Perampanel or Topiramate(within 1month before this registration) 9.Patients who underwent nuclear medicine examination within 1 week before this registration 10.Patients who underwent other clinical trials using unapproved nuclear medicine examination within 6 months before this registration 11.Patients who underwent other clinical trial within 12 weeks before this registration 12.Patients whom study doctors consider inappropriate

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To examine the differences in the distributions of AMPARs among the groups divided by seizure pattern in comparison with those of healthy subjects.

Secondary Outcome Measures

Name	Time	Method
1. To examine the differences in the distributions of AMPARs between the groups divided by seizure pattern in comparison with their FDG-PET data. 2. To examine the correlation in the expected foci between those identified by AMPA-PET and EEG/MEG.